1. Chateau T, Bonovas S, Le Berre C, Mathieu N, Danese S, Peyrin-Biroulet L. Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2019;13:1569-77.

https://doi.org/10.1093/ecco-jcc/jjz095

PMid:31076751 

2. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17-30.

PMid:31648971

3. Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40:S253-9.

https://doi.org/10.1016/S1590-8658(08)60534-4

PMid:18598997

4. Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47:485-93.

https://doi.org/10.1111/apt.14419

PMid:29250803 

5. Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, et al. Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the swiss IBD cohort study. Inflamm Bowel Dis. 2017;23:1174-81.

https://doi.org/10.1097/MIB.0000000000001109

PMid:28452862 

6. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29-34.

https://doi.org/10.1097/00004836-199607000-00009

PMid:8835896 

7. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1982-92.

https://doi.org/10.1097/MIB.0000000000000392

PMid:26154136 PMCid:PMC4511685

8. Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, et al. Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:1876-82.

https://doi.org/10.1093/ibd/izy065

PMid:29668916 

9. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-35

https://doi.org/10.1056/NEJM199710093371502

PMid:9321530 

10. Brynskov J, Nielsen OH, Ahnfelt-Rønne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig Dis. 1994;12:290-304.

https://doi.org/10.1159/000171464

PMid:7882549 

11. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251-9.

https://doi.org/10.1006/cyto.1995.0029

PMid:7640345 

12. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterol. 2008;135:1493-9.

https://doi.org/10.1053/j.gastro.2008.07.069

PMid:18848553 

13. Liu J, Sylwestrzak G, Ruggieri AP, DeVries A. Intravenous versus subcutaneous anti-TNF-alpha agents for Crohn's Disease: a comparison of effectiveness and safety. J Manag Care Spec Pharm. 2015;21:559-66.

https://doi.org/10.18553/jmcp.2015.21.7.559

PMid:26108380 

14. Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.

https://doi.org/10.1038/ctg.2015.63

PMid:26741065 PMCid:PMC4737871

15. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterol. 2007;132:52-65.

https://doi.org/10.1053/j.gastro.2006.11.041

PMid:17241859 

16. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-76.

https://doi.org/10.1056/NEJMoa050516

PMid:16339095 

17. Sandborn WJ. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord. 2007;7:S23-35.

PMid:17392636

18. Shahidi N, Bressler B, Panaccione R. The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis. Therap Adv Gastroenterol. 2016;9:330-8.

https://doi.org/10.1177/1756283X16635081

PMid:27134663 PMCid:PMC4830105

19. Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S, Atreya R, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - A nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43:1090-102.

https://doi.org/10.1111/apt.13594

PMid:27038247 

20. Krupka N, Baumgart DC. Designing biologic selectivity for inflammatory bowel disease - role of vedolizumab. Drug Des Devel Ther. 2015;9:147-54.

https://doi.org/10.2147/DDDT.S50348

PMid:25552903 PMCid:PMC4277125

21. Cichoż-Lach H, Michalak A, Kopertowska-Majchrzak M, Eder P, Stawczyk-Eder K, Waszak K, et al. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therap Adv Gastroenterol. 2021;14:17562848211036456.

https://doi.org/10.1177/17562848211036456

PMid:34484422 PMCid:PMC8411627

22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

https://doi.org/10.1371/journal.pmed.1000097

PMid:19621072 PMCid:PMC2707599

23. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13:147-53.

https://doi.org/10.1097/XEB.0000000000000054

PMid:26317388 

24. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81:580-5.

https://doi.org/10.1136/pgmj.2004.031633

PMid:16143688 PMCid:PMC1743347

25. Pouillon L, Van Stappen J, Bossuyt P, Danese S, Peyrin-Biroulet L. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?. Best Pract Res Clin Gastroenterol. 2018;32-33:17-25.

https://doi.org/10.1016/j.bpg.2018.05.006

PMid:30060934 

26. Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future. Nat Rev Gastroenterol Hepatol. 2020;17:365-76.

https://doi.org/10.1038/s41575-020-0293-9

PMid:32303700 

27. Ungureanu L, Cosgarea R, Badea MA, Vasilovici AF, Cosgarea I, Senila SC. Cutaneous manifestations of inflammatory bowel disease (Review). Exp Ther Med. 2020;20:31-7.

https://doi.org/10.3892/etm.2019.8321

PMid:32508989 PMCid:PMC7271697

28. Greuter T, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis. Expert Rev Gastroenterol Hepatol. 2019;13:307-17.

https://doi.org/10.1080/17474124.2019.1574569

PMid:30791773 

29. O'Neill ID. Off-label use of biologicals in the management of inflammatory oral mucosal disease. J Oral Pathol Med. 2008;37:575-81.

https://doi.org/10.1111/j.1600-0714.2008.00693.x

PMid:18764859 

30. Poulakos M, Machin JD, Pauly J, Grace Y. Vedolizumab: a new opponent in the battle against Crohns disease and ulcerative colitis. J Pharm Pract. 2016;29:503-15.

https://doi.org/10.1177/0897190015579610

PMid:25952593 

31. Grošelj D, Grabec I, Seme K, Ihan A, Ferkolj I. Prediction of clinical response to anti-TNF treatment by oral parameters in Crohn's disease. Hepatogastroenterology. 2008;55:112-9.

PMid:18507089

32. Hagan M, Cross RK. Safety of vedolizumab in the treatment of Crohns disease and ulcerative colitis. Expert Opin Drug Saf. 2015;14:1473-9.

https://doi.org/10.1517/14740338.2015.1063612

PMid:26138111 

33. Yi F, Chen M, Huang M, Li J, Zhao J, Li L, et al. The trend in newly diagnosed Crohn's disease and extraintestinal manifestations of Crohn's disease in central China: A retrospective study of a single center. Eur J Gastroenterol Hepatol. 2012;24:1424-9

https://doi.org/10.1097/MEG.0b013e3283583e5c

PMid:22895389 

34. O'Neill I. Guidance on the use of biological agents in the treatment of oral mucosal disease. Br J Dermatol. 2010;162:1410-1.

https://doi.org/10.1111/j.1365-2133.2010.09704.x

PMid:20163409 

35. Löfberg R, Louis E V, Reinisch W, Robinson AM, Kron M, Camez A, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis. 2012;18:1-9.

https://doi.org/10.1002/ibd.21663

PMid:21351211 

36. Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618-27.e3.

https://doi.org/10.1053/j.gastro.2014.05.008

PMid:24859203 

37. Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease: prevalence, presentation, and anti-TNF treatment. J Pediatr Gastroenterol Nutr. 2017;65:200-6.

https://doi.org/10.1097/MPG.0000000000001455

PMid:27801751 

38. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int. 2005;25:406-10.

https://doi.org/10.1007/s00296-004-0467-8

PMid:15309501 

39. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136:1182-97.

https://doi.org/10.1053/j.gastro.2009.02.001

PMid:19249397 

40. Williams H, Walker D, Orchard TR. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2008;10:597-605.

https://doi.org/10.1007/s11894-008-0108-6

PMid:19006617